BOSTON, April 10 /PRNewswire/ -- PAREXEL Clinical Research Services, a business unit of PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, today announced that Dr. Denis R. Miller, a foremost oncology and hematology expert, has joined the Company as a Senior Medical Director. Dr. Miller will act as clinical practice leader and provide consultation to clients sponsoring clinical trials in hematology and oncology.
"Dr. Miller's appointment to our global team of therapeutic experts demonstrates PAREXEL's commitment to expanding our leadership in the oncology field," said Mark A. Goldberg, President of Clinical Research Services and Perceptive Informatics at PAREXEL International. "In addition to enhancing our in-depth therapeutic knowledge, we are focused on advancing our clients' cancer treatments through the integration of medical expertise with our world-class medical imaging capabilities, and Dr. Miller will be a vital asset in that effort."
During the 10 year period prior to joining PAREXEL, Dr. Miller worked at several leading pharmaceutical companies, including Hoffmann-La Roche, Inc. (Roche) and Johnson & Johnson, as well as clinical research organizations, where he held senior positions in pharmaceutical R&D and clinical oncology. He has served in leadership roles at premier cancer centers, medical centers and hospitals including as Chairman, Department of Pediatrics at Memorial Sloan Kettering Cancer Center. Dr. Miller holds AB and MD degrees from Cornell University, and was a Fulbright Scholar at the University of London, St. Mary's Medical School. He completed his post-graduate residency and fellowship training at Children's Hospital Medical Center and Harvard Medical School, and is Board Certified in pediatrics and pediatric hematology/oncology. Dr. Miller is currently Clinical Professor of Pediatrics at the Robert Wood Johnson School of Medicine and Research Associate at the Cancer Institute of New Jersey. Dr. Miller serves on editorial boards of British Journal of Haematology and American Journal of Clinical Oncology. He has authored more than 300 books and articles, including a textbook on pediatric blood diseases. He was a president of the American Society of Pediatric Hematology/Oncology, and is a long-standing member of several oncology associations.
With in-depth oncology expertise, PAREXEL has contributed to more than half of the top selling oncology drugs. Supplementing the expertise of PAREXEL's oncology, hematology and medical imaging teams, Dr. Miller will provide medical insight to clients throughout the clinical development continuum, ranging from development of clinical plans and design of protocols to the conduct of trials. PAREXEL will also leverage Dr. Miller's experience and relationships with leading cancer centers and key opinion leaders in its ongoing collaborative efforts. Working closely with PAREXEL's subsidiary Perceptive Informatics, PAREXEL Clinical Research Services helps clients apply advanced medical imaging techniques in clinical development to support regulatory endpoints, provide early evidence of efficacy, and accelerate go/no-go decisions.
About PAREXEL
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 51 locations throughout 39 countries around the world, and has approximately 5,360 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment ("Statement 123R"), which could change the Company's current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company's books for future financial periods; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2005 as filed with the SEC on February 9, 2006, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Media Contact: Jennifer Baird, Director of Public Relations PAREXEL International Tel: +1.781.434.4409 Email: Jennifer.Baird@PAREXEL.com
PAREXEL Clinical Research ServicesCONTACT: Jennifer Baird, Director of Public Relations of PAREXELInternational, +1-781-434-4409, Jennifer.Baird@PAREXEL.com
Web site: http://www.PAREXEL.com/
